المؤلفون: Lacour, Jean-Philippe, Khemis, Abdallah, Giordano-Labadie, Francoise, Martin, Ludovic, Staumont, delphine, Hacard, Florence, Tian, Haijun, Mcbride, Doreen, Hollis, Kelly, Hunter, Shannon, Martin, Laurent, Lamirand, Audrey, Le Guen, Sophie, Balp, Maria-Magdalena, Berard, Frederic

المساهمون: Université Côte d'Azur UniCA, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, Centre Hospitalier Universitaire d'Angers CHU Angers, Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011, Université Claude Bernard Lyon 1 UCBL

مصطلحات موضوعية: chronic idiopathic urticaria, chronic spontaneous urticaria, observational study, health economics, health-related quality of life, angioedema

الوصف: Data on the clinical burden of chronic spontaneous urticaria (CSU) and economic consequences are lacking in France. To characterize the clinical and economic burden of CSU in symptomatic patients despite treatment by analysing data of French patients from the ASSURE-CSU study. ASSURE-CSU was an international observational study that included CSU patients with symptoms that lasted for 12 months or more despite treatment. Disease characteristics and healthcare resource use were obtained from medical records. Data on disease history, health-related quality of life (HR-QoL), and work productivity were collected from a patient survey. A total of 101 patients were analysed (76.2% female; mean age: 48.9 years) with moderate to severe disease (UAS7 score ≥16) in 43.4% and angioedema in 72.3%. The mean (S.D.) total scores of Chronic Urticaria Quality of Life (CU-Q2 ; 28

العلاقة: European Journal of Dermatology; Eur J Dermatol; http://hdl.handle.net/20.500.12210/104916Test

الإتاحة: https://doi.org/20.500.12210/104916Test
https://hdl.handle.net/20.500.12210/104916Test

المؤلفون: Faiz, Sarah, Giovannelli, Jonathan, Podevin, Celine, Jachiet, Marie, Bouaziz, Jean-David, Reguiai, Ziad, Nosbaum, Audrey, Lasek, Audrey, Ferrier Le Bouedec, Marie-Christine, Du Thanh, Aurelie, Raison-Peyron, Nadia, Tetart, Florence, Duval-Modeste, Anne-Benedicte, Misery, Laurent, Aubin, Francois, Dompmartin, Anne, Morice, Cecile, Droitcourt, Catherine, Soria, Angele, Arnault, Jean-Philippe, Delaunay, Juliette, Mahe, Emmanuel, Richard, Marie-Aleth, Schoeffler, Amelie, Lacour, Jean-Philippe, Begon, Edouard, Walter-Lepage, Amelie, Dillies, Anne-Sophie, Rappelle-Duruy, Sandrine, Barete, Stephane, Bellon, Nathalia, Beneton, Nathalie, Valois, Aude, Barbarot, Sebastien, Seneschal, Julien, staumont, delphine

المساهمون: CHU Lille, Inserm, Université de Lille, Lille Inflammation Research International Center (LIRIC) - U995, Lille Inflammation Research International Center - U 995 LIRIC, Université Paris Diderot - Paris 7 UPD7, Université Claude Bernard Lyon 1 UCBL, Université de Clermont-Ferrand, Université de Montpellier UM, Université de Franche-Comté UFC, Université de Rennes UR, Sorbonne Université SU, Aix Marseille Université AMU, Sorbonne Universités (COMUE), Université de Bordeaux UB

الوصف: BACKGROUND: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10 , respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm ) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10 ). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. CONCLUSIONS: No control group, missing data. CONCLUSIONS: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia. ; 81

العلاقة: Journal of The American Academy of Dermatology; J. Am. Acad. Dermatol.; http://hdl.handle.net/20.500.12210/13774Test

الإتاحة: https://doi.org/20.500.12210/13774Test
https://hdl.handle.net/20.500.12210/13774Test

المؤلفون: Costedoat, Ingrid, Wallaert, Martin, Gaultier, Aurélie, Vasseur, Robin, Vanhaecke, Clelia, Viguier, Manuelle, Cordelette, Charles, Denoyer, Alexandre, Ferrier Le Bouëdec, Marie-Christine, Coutu, Adrien, Lamiaux, Marie, Tran, Thi-Ha-Chau, Lacour, Jean-Philippe, Elmaleh, Valerie, Tetart, Florence, Gueudry, Julie, Tauber, Marie, Giordano-Labadie, Françoise, Cassagne, Myriam, Nosbaum, Audrey, Ouilhon, Coralie, Jachiet, Marie, Tadayoni, Ramin, Dezoteux, Frédéric, Staumont, delphine, Bouleau, Julien, Labalette, Pierre, Doan, Serge, Soria, Angele, Mortemousque, Bruno, Seneschal, Julien, Barbarot, Sebastien

المساهمون: Université de Lille, Inserm, CHU Lille, CHU Bordeaux, Centre Hospitalier Universitaire de Nantes CHU Nantes, Hôpital universitaire Robert Debré Reims, CHU Clermont-Ferrand, Université catholique de Lille UCL, Centre Hospitalier Universitaire de Nice CHU Nice, CHU Rouen, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, Hospices Civils de Lyon HCL, Centre International de Recherche en Infectiologie CIRI, Centre Hospitalier Lyon Sud CHU - HCL CHLS, Hopital Saint-Louis AP-HP AP-HP, Hôpital Lariboisière-Fernand-Widal APHP, Institute for Translational Research in Inflammation - U 1286 INFINITE (Ex-Liric), Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Centre Hospitalier Régional Universitaire CHU Lille CHRU Lille, CHU Tenon AP-HP

الوصف: Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events. Methods A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis. Limitations Our follow-up period was 16 weeks and some late-onset time effects may still occur. Conclusion This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.

العلاقة: Journal of the European Academy of Dermatology and Venereology; J Eur Acad Dermatol Venereol; http://hdl.handle.net/20.500.12210/100638Test

الإتاحة: https://doi.org/20.500.12210/100638Test
https://hdl.handle.net/20.500.12210/100638Test

المؤلفون: Montaudié, Henri, Le Duff, Florence, Butori, Catherine, Hofman, Véronique, Fontas, Eric, Roger-Cruzel, Coralie, Bahadoran, Philippe, Perrot, Jean-Luc, Desmedt, Eve, Legoupil, Délphine, Passeron, Thierry, Lacour, Jean-Philippe

المساهمون: Inserm, Université de Lille, CHU Lille, Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 ONCO-THAI

الوصف: 82;3

العلاقة: Journal of The American Academy of Dermatology; http://hdl.handle.net/20.500.12210/58265Test

الإتاحة: https://doi.org/20.500.12210/58265Test
https://hdl.handle.net/20.500.12210/58265Test

المؤلفون: Lacour, Jean-Philippe, Khemis, Abdallah, Giordano-Labadie, Françoise, Martin, Ludovic, Staumont-Sallé, Delphine, Hacard, Florence, Tian, Haijun, Mcbride, Doreen, Hollis, Kelly, Hunter, Shannon, Martin, Laurent, Lamirand, Audrey, Le Guen, Sophie, Balp, Maria-Magdalena, Bérard, Frédéric

المساهمون: MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale MITOVASC, Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 RNMCD, Centre Hospitalier Lyon Sud CHU - HCL CHLS, Institut NeuroMyoGène INMG, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination

الوصف: Data on the clinical burden of chronic spontaneous urticaria (CSU) and economic consequences are lacking in France. To characterize the clinical and economic burden of CSU in symptomatic patients despite treatment by analysing data of French patients from the ASSURE-CSU study. ASSURE-CSU was an international observational study that included CSU patients with symptoms that lasted for 12 months or more despite treatment. Disease characteristics and healthcare resource use were obtained from medical records. Data on disease history, health-related quality of life (HR-QoL), and work productivity were collected from a patient survey. A total of 101 patients were analysed (76.2% female; mean age: 48.9 years) with moderate to severe disease (UAS7 score ≥16) in 43.4% and angioedema in 72.3%. The mean (S.D.) total scores of Chronic Urticaria Quality of Life (CU-QoL) and Dermatology Life Quality Index (DLQI) were 37.7 (22.3) and 9.7 (6.9), respectively, thus indicating a significant impact of the disease on HR-QoL. Mean absenteeism and presenteeism were 6.4% and 20.8%, respectively, with a mean loss of work productivity estimated at 20.7%. The mean (S.D.) total direct cost of CSU was €2,397 per patient per year and was mainly driven by therapies (€1,435) and inpatient costs (€859). The indirect costs for four weeks were mainly presenteeism (€421) and loss of work productivity (€420). CSU significantly impairs HR-QoL, which increases with the severity of the disease. The direct and indirect costs for the management of symptomatic CSU are an important economic burden. ; 28 ; 6

العلاقة: EUROPEAN JOURNAL OF DERMATOLOGY; http://hdl.handle.net/20.500.12210/112806Test

الإتاحة: https://doi.org/20.500.12210/112806Test
https://hdl.handle.net/20.500.12210/112806Test